Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
37,871,761
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
5,283,801
-
Shares change
-
+877,875
-
Total reported value, excl. options
-
$16,487,763
-
Value change
-
+$2,703,700
-
Put/Call ratio
-
1.68%
-
Number of buys
-
29
-
Number of sells
-
-12
-
Price
-
$3.12
Significant Holders of Anixa Biosciences Inc - Common Stock (ANIX) as of Q1 2024
68 filings reported holding ANIX - Anixa Biosciences Inc - Common Stock as of Q1 2024.
Anixa Biosciences Inc - Common Stock (ANIX) has 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,283,801 shares
of 37,871,761 outstanding shares and own 13.95% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1,392,906 shares), Laird Norton Wetherby Trust Company, LLC (604,235 shares), UBS Group AG (536,307 shares), MISSION WEALTH MANAGEMENT, LP (502,420 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (340,951 shares), GEODE CAPITAL MANAGEMENT, LLC (320,148 shares), Long Focus Capital Management, LLC (165,701 shares), BlackRock Inc. (154,662 shares), JANE STREET GROUP, LLC (121,924 shares), and BANK OF AMERICA CORP /DE/ (116,914 shares).
This table shows the top 58 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.